Two experimental drugs join forces against hard-to-treat lymphoma
NCT ID NCT02651662
First seen Feb 02, 2026 · Last updated May 23, 2026 · Updated 14 times
Summary
This early-stage study tests two experimental drugs, odronextamab and cemiplimab, in about 105 people with aggressive B-cell lymphoma that has come back or not responded to prior treatments. The main goal is to see if the combination is safe and tolerable, and to find the best dose. Researchers will also monitor side effects, how the drugs work in the body, and whether the body makes antibodies against them.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AGGRESSIVE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan, 49546, United States
-
Chaim Sheba Medical Center
Ramat Gan, 5265601, Israel
-
Copernicus Memorial Hospital
Lodz, 93-513, Poland
-
Dana Farber/Harvard Cancer Center - PO box 849168
Boston, Massachusetts, 02215, United States
-
Hadassah Medical Center
Jerusalem, 91200, Israel
-
Harvard Medical School - Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
-
Hospital Clinico Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
Hospital Universitario Marques de Valdecilla
Santander, Cantabria, 39008.0, Spain
-
Hospital Universitario Puerta de Hierro - Majadahonda
Majadahonda, Madrid, 28222, Spain
-
Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Madrid, 28223, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, 08041, Spain
-
Institut Catala dOncologia (ICO Hospitalet)
Barcelona, 08908, Spain
-
Johns Hopkins University
Baltimore, Maryland, 21205, United States
-
MD Anderson Cancer Center- Madrid
Madrid, 28033, Spain
-
Medical University Vienna
Vienna, 1190, Austria
-
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Warszawa
Warsaw, 02781, Poland
-
Pratia MCM Krakow
Krakow, Malopolska, 30-510, Poland
-
Pratia Onkologia Katowice
Katowice, 40-519, Poland
-
Soroka
Beersheba, 84101, Israel
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
-
Uniklinikum Salzburg (LKH) Universitatsklinik fur Innere Medizin III
Salzburg, 5020, Austria
-
Universitatsklinikum Jena
Jena, 7747, Germany
-
Universitatsklinikum Schleswig-Holstein, Campus Kiel
Kiel, 24105, Germany
-
University Hospital Frankfurt
Frankfurt am Main, 60590, Germany
-
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106, United States
-
Uniwersyteckie Centrum Kliniczne
Gdansk, Pomeranian Voivodeship, 80-952, Poland
Conditions
Explore the condition pages connected to this study.